Keywords: Probes & Targets, Cancer
Motivation: Molecular imaging holds revolutionary significance in the diagnosis and treatment of tumors.
Goal(s): Clinical trials targeting immune checkpoint receptors with immune checkpoint blockade (ICB) therapies has encountered limited efficacy in pancreatic cancer.
Approach: MRI-guide ICB therapy (MRGIT) strategy for enhancing and guiding anti-PD-L1 therapy was proposed.
Results: The successful inhibition of tumor growth via MRGIT strategy in pancreatic tumor models demonstrates that it may be efficiently reverse the immunosuppressive PDAC and improve the ICB therapy with the employment of MRI technology.
Impact: The MRGIT strategy bridging the antitumor immune response with the MRI technique, which devised a potent tool that holds great promise for improving cancer diagnosis and facilitating the development of personalized treatment strategies tailored to individual patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords